Utzschneider, Kristina M <br/><br/>
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.  [electronic resource] 

 -  Diabetes care  Jan 2008 
 - 108-13 p.  digital 
<br/><br/> Publication Type: Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1935-5548 
<br/><br/><label>Standard No.: </label>10.2337/dc07-1441  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--analogs & derivatives<br/>Blood Glucose--drug effects<br/>Dipeptidyl-Peptidase IV Inhibitors--therapeutic use<br/>Female<br/>Glucose Intolerance--blood<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Insulin--blood<br/>Insulin Secretion<br/>Insulin-Secreting Cells--drug effects<br/>Male<br/>Middle Aged<br/>Nitriles--therapeutic use<br/>Placebos<br/>Pyrrolidines--therapeutic use<br/>Single-Blind Method<br/>Vildagliptin